Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria:...
Transcript of Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria:...
![Page 1: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/1.jpg)
Modified Recist Criteria:Applications in Clinical
Practice
DENNIS FOLEY
MEDICAL COLLEGE WISCONSIN
![Page 2: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/2.jpg)
Response Evaluation Criteria in Solid Tumors ( RECIST )
Year 2000 GOAL STANDARDISE AND SIMPLIFY
TUMOR RESPONSE CRITERIA
MAJOR APPLICATION ONCOLOGIC CLINICAL TRIALS
INVOLVING MULTIFOCAL SOLID TUMORS
![Page 3: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/3.jpg)
WHO vs. RECIST Criteria WHO (2 dimensions) :
Single lesion: multiply the longest diameter by the greatest perpendicular diameter
Multiple lesions: sum the products of all measured lesions
RECIST (1 dimension): Single lesion: longest diameter of target lesion
Multiple lesions: sum of diameters of all targets
Response WHO RECIST
Complete Response Disappearance of all lesions
Partial Response >50% decrease >30% decrease
Stable Ds Neither PR or PD Neither PR or PD
Progression > 25% increase > 20% increase
![Page 4: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/4.jpg)
METASTATIC UROTHELIAL CANCER
![Page 5: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/5.jpg)
Recist 1.1 Criteria (1)Year 2009
MEASURABLE LESIONS 2 PER ORGAN, MAXIMUM 5
LYMPH NODE DISEASE SHORT AXIS DIMENSION >15 MM <10 MM ( NON MEASURABLE ) 10-15 MM ( NON TARGET )
DISEASE PROGRESSION 20% INCREASE IN SUM OF THE TARGET
LESIONS
![Page 6: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/6.jpg)
Recist 1.1 (3)Additional Issues
TUMOR NECROSIS, LIQUEFACTION, HEMORRHAGE TUMOR DIMENSIONS STABLE OR ENLARGED
CAVITATION
PROGRESSION OF NON TARGET LESIONS
METABOLIC RESPONSE ( CT PET )
Nishino et al: AJR 2010; 195;281-289
![Page 7: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/7.jpg)
METASTATIC GASTRIC GASTRO INTESTINAL STROMAL TUMOR
![Page 8: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/8.jpg)
MULTIPHASE HEPATIC CT
0 4515 30 60 755 cc/sec 30 secs
EARLY ARTERIAL PHASELATE ARTERIAL PHASEPORTAL VENOUS PHASE
![Page 9: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/9.jpg)
EARLY ARTERIAL
LATE ARTERIAL/ PVIF
HEPATIC
![Page 10: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/10.jpg)
CIRRHOSIS HEP B POS HEPATOCELLULAR CA THAD
![Page 11: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/11.jpg)
ARTERIO PORTAL FISTULA
![Page 12: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/12.jpg)
HEPATOCELLULAR CARCINOMA
LATE ARTERIAL PHASE
HEPATIC PHASE
![Page 13: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/13.jpg)
1 YEAR FOLLOW UPLATE ARTERIAL PHASE
HEPATIC PHASE
![Page 14: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/14.jpg)
AASLD/EASL criteria for HCC
Size Characteristics c/w HCC Further workup of equivocal lesions
> 2 cm (1) Arterial enhancement with venous washout or
(2) AFP >200 ng/mL
Biopsy
1-2 cm (1) dynamic studies (CT or MRI) demonstrating characteristic enhancement
Biopsy
< 1cm Arterial enhancement may not correspond to HCC
Surveillance imaging
![Page 15: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/15.jpg)
Reporting of indeterminate lesions
< 1 cm
1‐2 cm
![Page 16: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/16.jpg)
Modified RECIST
WHO and RECIST criteria do not accurately assess anti-tumor therapies which do not result in tumor shrinkage
mRECIST recommended by AASLD
Response WHO RECIST mRECIST
Complete Response Disappearance of all lesions Disappearance of intratumoral arterial
enhancementPartial Response >50% decrease >30% decrease >30% decrease in
viable target lesionsStable Ds Neither PR or PD Neither PR or PD Neither PR or PD
Progression > 25% increase > 20% increase >20% increase in viable target lesions
![Page 17: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/17.jpg)
Reporting of Post-Treatment Response
Longest Overall TumorDiameter
Longest Viable Tumor Diameter
![Page 18: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/18.jpg)
Modified Recist Target Lesions
RECIST MEASURABLE ACCURATLY MEASURED IN ONE
DIMENSION AS AT LEAST 1 CM
SUITABLE FOR REPEAT MEASUREMENT
LESION DEMONSTRATES INTRA TUMORAL ARTERIAL ENHANCEMENT ON CONTRAST ENHANCED CT OR MRI
![Page 19: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/19.jpg)
HCC : PRE , POST SELECTIVE ARTERIAL THERAPY WITH DEB
IMMEDIATE POST RX
3 MONTH SURVEILLANCE
![Page 20: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/20.jpg)
SERIAL SURVEILLANCE
![Page 21: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/21.jpg)
Modified Recist Non Target Lesions
RECIST NON MEASURABLE INFILTRATIVE LESIONS WITH ILL
DEFINED BORDERS
PREVIOUSLY TREATED BY LOCOREGIONAL OR SYSTEMIC THERAPY WITH MULTIFOCAL AREAS OF NECROSIS
![Page 22: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/22.jpg)
HCC POST ABLATION
![Page 23: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/23.jpg)
HCC PRE / POST TACE
![Page 24: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/24.jpg)
HCC TACE VIABLE TUMOR
PRE CONTRAST
LATE ARTERIAL PHASE
HEPATIC PHASE
![Page 25: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/25.jpg)
HCC SPONTANEOUS HEMORRHAGE
![Page 26: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/26.jpg)
INFILTRATIVE HCC
![Page 27: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/27.jpg)
INFILTRATIVE HCC TUMOR THROMUS
PULMONARY METASTASIS
![Page 28: Modified Recist Criteria: Applications in Clinical … Modified Recist...Modified Recist Criteria: Applications in Clinical ... PVIF HEPATIC. CIRRHOSIS ... 2011 Presentation Modified](https://reader034.fdocuments.net/reader034/viewer/2022052206/5adf151a7f8b9ab4688bafc0/html5/thumbnails/28.jpg)
Summary
RECIST CRITERIA DEVELOPED FOR USE IN ONCOLOGY CLINICAL TRIALS
RECOGNITION OF TARGET AND NON TARGET LESIONS AND ACCURATE MEASUREMENTS OF TARGET LESIONS ON SERIAL STUDIES ARE BENCHMARKS IN ASSESSING TUMOR RESPONSE
MANY VARIABLES APART FROM TUMOR DIMENSIONS THAT REFLECT RESPONSE